Yale Catriona, Chief Development Officer at Akero Therapeutics ($AKRO), sold shares on the open market 15 times over the last year, totaling about $2.5 million. Her most recent sale occurred on September 11, 2025. These transactions rank her 3,038th among 11,678 insiders for sales volume, below the average of $8.6 million per seller and 6.4 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 84051 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.10% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 33421 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.04% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 74053 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.09% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 52785 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.06% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Common Stock | 27227 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.03% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Common Stock | 47573 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.06% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 3421 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 5032 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.01% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 2328 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 70279 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.09% |
| Dec. 9, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | D | Stock Option (Right to Buy) | 131205 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.16% |
| Nov. 4, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 4739 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.01% |
| Nov. 4, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 3527 | $0.00 | 0.0000 | 82,316,179 | 100.00% | 0.00% |
| Nov. 4, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 4739 | $21.10 | 74,800.0000 | 82,316,179 | 6.76% | 0.01% |
| Nov. 4, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 3527 | $28.35 | 70,061.0000 | 82,316,179 | 5.30% | 0.00% |
| Sept. 11, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 659 | $43.02 | 90,829.0000 | 79,620,128 | 0.72% | 0.00% |
| July 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 131,205.0000 | 79,620,128 | 7.08% | 0.01% |
| July 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 1342 | $53.47 | 91,488.0000 | 79,620,128 | 1.45% | 0.00% |
| July 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 8658 | $52.87 | 92,830.0000 | 79,620,128 | 8.53% | 0.01% |
| July 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $19.87 | 101,488.0000 | 79,620,128 | 10.93% | 0.01% |
| June 30, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | A | Common Stock | 890 | $23.87 | 91,488.0000 | 79,620,128 | 0.98% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 79,620,128 | 100.00% | 0.01% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 895 | $55.52 | 92,231.0000 | 79,620,128 | 0.96% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2895 | $54.80 | 93,126.0000 | 79,620,128 | 3.01% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $21.10 | 102,231.0000 | 79,620,128 | 10.84% | 0.01% |
| June 18, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 1633 | $54.84 | 90,598.0000 | 79,620,128 | 1.77% | 0.00% |
| June 16, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 6210 | $53.78 | 96,021.0000 | 79,620,128 | 6.07% | 0.01% |
| June 10, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2803 | $54.00 | 92,231.0000 | 79,620,128 | 2.95% | 0.00% |
| May 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 4384 | $39.91 | 95,034.0000 | 79,620,128 | 4.41% | 0.01% |
| May 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $21.10 | 105,034.0000 | 79,620,128 | 10.52% | 0.01% |
| May 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2837 | $38.20 | 102,197.0000 | 79,620,128 | 2.70% | 0.00% |
| May 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2779 | $39.46 | 99,418.0000 | 79,620,128 | 2.72% | 0.00% |
| May 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 79,620,128 | 50.00% | 0.01% |
| April 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 9073 | $21.10 | 104,107.0000 | 79,620,128 | 9.55% | 0.01% |
| April 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 7873 | $37.80 | 96,234.0000 | 79,620,128 | 7.56% | 0.01% |
| April 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 1200 | $38.62 | 95,034.0000 | 79,620,128 | 1.25% | 0.00% |
| April 15, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 9073 | $0.00 | 20,000.0000 | 79,620,128 | 31.21% | 0.01% |
| March 17, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $21.10 | 105,034.0000 | 79,620,128 | 10.52% | 0.01% |
| March 17, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 8201 | $44.70 | 96,833.0000 | 79,620,128 | 7.81% | 0.01% |
| March 17, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 1799 | $45.05 | 95,034.0000 | 79,620,128 | 1.86% | 0.00% |
| March 17, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 79,620,128 | 100.00% | 0.01% |
| March 12, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 614 | $44.88 | 95,034.0000 | 79,620,128 | 0.64% | 0.00% |
| Feb. 18, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $21.10 | 105,648.0000 | 79,620,128 | 10.46% | 0.01% |
| Feb. 18, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 9100 | $49.79 | 96,548.0000 | 79,620,128 | 8.61% | 0.01% |
| Feb. 18, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 900 | $50.63 | 95,648.0000 | 79,620,128 | 0.93% | 0.00% |
| Feb. 18, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 79,620,128 | 50.00% | 0.01% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 9074 | $0.00 | 20,000.0000 | 0 | 31.21% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 17000 | $55.16 | 132,238.0000 | 0 | 11.39% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 9250 | $55.95 | 122,988.0000 | 0 | 6.99% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 27340 | $57.02 | 95,648.0000 | 0 | 22.23% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 16849 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 15172 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 641 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 20928 | $0.00 | 52,785.0000 | 0 | 28.39% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 49074 | $21.10 | 144,722.0000 | 0 | 51.31% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 25907 | $55.15 | 118,815.0000 | 0 | 17.90% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 14467 | $55.95 | 104,348.0000 | 0 | 12.18% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 8700 | $57.01 | 95,648.0000 | 0 | 8.34% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 33,421.0000 | 0 | 37.44% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 21569 | $21.09 | 149,238.0000 | 0 | 16.89% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 15172 | $6.36 | 127,669.0000 | 0 | 13.49% | 0.00% |
| Jan. 27, 2025 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 16849 | $0.62 | 112,497.0000 | 0 | 17.62% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 9074 | $21.10 | 104,722.0000 | 0 | 9.49% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 9074 | $29.11 | 95,648.0000 | 0 | 8.66% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | A | Stock Option (Right to Buy) | 73700 | $0.00 | 73,700.0000 | 0 | 9999.99% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 9074 | $0.00 | 20,000.0000 | 0 | 31.21% | 0.00% |
| Dec. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | A | Common Stock | 24300 | $0.00 | 95,648.0000 | 0 | 34.06% | 0.00% |
| Dec. 10, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2810 | $30.79 | 71,348.0000 | 0 | 3.79% | 0.00% |
| Nov. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 300 | $28.82 | 74,158.0000 | 0 | 0.40% | 0.00% |
| Nov. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 9061 | $0.00 | 53,421.0000 | 0 | 14.50% | 0.00% |
| Nov. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 9061 | $21.10 | 83,219.0000 | 0 | 12.22% | 0.00% |
| Nov. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 8761 | $27.69 | 74,458.0000 | 0 | 10.53% | 0.00% |
| Nov. 6, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 10000 | $35.19 | 74,158.0000 | 0 | 11.88% | 0.00% |
| Nov. 6, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $0.62 | 84,158.0000 | 0 | 13.48% | 0.00% |
| Nov. 6, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 1110 | $0.00 | 16,849.0000 | 0 | 6.18% | 0.00% |
| Nov. 6, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 8890 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 1, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 15485 | $32.62 | 74,158.0000 | 0 | 17.27% | 0.00% |
| Nov. 1, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 15485 | $0.00 | 41,781.0000 | 0 | 27.04% | 0.00% |
| Oct. 30, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 4515 | $0.00 | 57,266.0000 | 0 | 7.31% | 0.00% |
| Nov. 1, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 15485 | $21.10 | 89,643.0000 | 0 | 20.88% | 0.00% |
| Oct. 30, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 4515 | $32.53 | 74,158.0000 | 0 | 5.74% | 0.00% |
| Oct. 30, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 4515 | $21.10 | 78,673.0000 | 0 | 6.09% | 0.00% |
| Oct. 14, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 5000 | $0.62 | 80,294.0000 | 0 | 6.64% | 0.00% |
| Oct. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 14825 | $0.62 | 90,119.0000 | 0 | 19.69% | 0.00% |
| Oct. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 14525 | $30.50 | 75,594.0000 | 0 | 16.12% | 0.00% |
| Oct. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 300 | $30.93 | 75,294.0000 | 0 | 0.40% | 0.00% |
| Oct. 14, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 6136 | $30.03 | 74,158.0000 | 0 | 7.64% | 0.00% |
| Oct. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 4825 | $0.00 | 13,890.0000 | 0 | 25.78% | 0.00% |
| Oct. 14, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 8,890.0000 | 0 | 36.00% | 0.00% |
| Oct. 15, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 17,959.0000 | 0 | 35.77% | 0.00% |
| Sept. 20, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 5500 | $0.00 | 27,959.0000 | 0 | 16.44% | 0.00% |
| Sept. 20, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 5500 | $0.62 | 80,794.0000 | 0 | 7.30% | 0.00% |
| Sept. 20, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 5500 | $27.65 | 75,294.0000 | 0 | 6.81% | 0.00% |
| Sept. 17, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 2037 | $0.62 | 77,331.0000 | 0 | 2.71% | 0.00% |
| Sept. 17, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2037 | $27.55 | 75,294.0000 | 0 | 2.63% | 0.00% |
| Sept. 18, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 3871 | $0.62 | 79,165.0000 | 0 | 5.14% | 0.00% |
| Sept. 18, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 3871 | $27.56 | 75,294.0000 | 0 | 4.89% | 0.00% |
| Sept. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 2485 | $0.00 | 39,367.0000 | 0 | 5.94% | 0.00% |
| Sept. 17, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 2037 | $0.00 | 37,330.0000 | 0 | 5.17% | 0.00% |
| Sept. 18, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 3871 | $0.00 | 33,459.0000 | 0 | 10.37% | 0.00% |
| Sept. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 2485 | $0.62 | 77,779.0000 | 0 | 3.30% | 0.00% |
| Sept. 16, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2485 | $27.52 | 75,294.0000 | 0 | 3.19% | 0.00% |
| Sept. 10, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 637 | $26.18 | 75,294.0000 | 0 | 0.84% | 0.00% |
| Sept. 3, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 949 | $27.61 | 75,931.0000 | 0 | 1.23% | 0.00% |
| Sept. 3, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 949 | $0.00 | 18,715.0000 | 0 | 4.83% | 0.00% |
| Sept. 3, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 949 | $0.62 | 76,880.0000 | 0 | 1.25% | 0.00% |
| Aug. 23, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 8851 | $27.53 | 75,931.0000 | 0 | 10.44% | 0.00% |
| Aug. 26, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 5200 | $0.00 | 19,664.0000 | 0 | 20.91% | 0.00% |
| Aug. 23, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 8851 | $0.00 | 24,864.0000 | 0 | 26.25% | 0.00% |
| Aug. 26, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 5200 | $27.51 | 75,931.0000 | 0 | 6.41% | 0.00% |
| Aug. 26, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 5200 | $0.62 | 81,131.0000 | 0 | 6.85% | 0.00% |
| Aug. 23, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 8851 | $0.62 | 84,782.0000 | 0 | 11.66% | 0.00% |
| June 28, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | A | Common Stock | 1064 | $19.94 | 75,931.0000 | 0 | 1.42% | 0.00% |
| June 11, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 2825 | $22.64 | 74,867.0000 | 0 | 3.64% | 0.00% |
| March 13, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 723 | $28.33 | 77,692.0000 | 0 | 0.92% | 0.00% |
| March 4, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | S | Common Stock | 20646 | $35.49 | 78,415.0000 | 0 | 20.84% | 0.00% |
| March 4, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10646 | $21.09 | 99,061.0000 | 0 | 12.04% | 0.00% |
| March 4, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Common Stock | 10000 | $6.36 | 88,415.0000 | 0 | 12.75% | 0.00% |
| March 4, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10646 | $0.00 | 74,354.0000 | 0 | 12.52% | 0.00% |
| March 4, 2024 | Akero Therapeutics, Inc. | $AKRO | Yale Catriona | Chief Development Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 15,172.0000 | 0 | 39.73% | 0.00% |